NAGE — Niagen Bioscience Inc

Niagen Bioscience Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: $31.5 million, a 5% year-over-year increase (excluding divested reference standard business).
• Net Income: $6.3 million ($0.08 per share), up from $0.07 per share in Q1 2025.
• Cash Position: $66.5 million with no debt; total working capital increased to $82.3 million.
• Gross Margin: Improved to 63.5%, up 10 basis points from the previous year.
• E-commerce Growth: Core e-commerce business grew 14% year-over-year, with direct-to-consumer website growth outpacing Amazon.

2. Strategic Updates and Business Highlights:

• Product Launches:
  • Launched the Niagen Plus at-home injection kit, which has received positive early consumer response.
  • Pilot-launched Niagen NanoCloud skincare product, with strong initial demand and nearly sold out.
• Scientific Recognition: NIAGEN received a published USP dietary supplement ingredient monograph, establishing a quality benchmark in the industry.
• Market Awareness: Increased media coverage and recognition of NAD supplementation benefits, enhancing brand visibility.
• Research Initiatives: Continued investment in clinical studies and participation in scientific discussions on NAD's health implications.

3. Forward Guidance and Outlook:

• Revenue Growth: Reaffirmed guidance of 10% to 15% year-over-year growth for 2026.
• E-commerce as Growth Engine: Anticipated consistent growth from e-commerce and innovative product launches.
• Marketing Investments: Increased spending on marketing and advertising to support brand awareness and new product launches.
• General and Administrative Expenses: Revised outlook to expect an increase of $3 million to $4 million year-over-year.

4. Challenges and Points of Concern:

• Customer Order Fluctuations: Noted reduced orders from two major customers impacting overall growth.
• Competitive Pressures: Increased competition from NMN products, which have gained market presence, particularly on Amazon, impacting NIAGEN sales and customer acquisition costs.
• Operational Cash Flow: Net cash used by operations was $1.2 million, contrasting with $7.9 million generated in the same period last year, primarily due to inventory investments and timing of customer orders.

5. Notable Q&A Insights:

• NMN Market Impact: CEO Rob Fried expressed concerns about the rising NMN competition affecting NIAGEN sales, noting that NMN products often do not meet quality standards.
• IV Clinic Expansion: NIAGEN is currently in 1,200 clinics, with strong order and repeat rates, primarily among affluent consumers.
• Telehealth Launch Response: Initial consumer response to the Niagen Plus IV injectable launch has been enthusiastic, with plans to expand distribution once regulatory issues are resolved.
• Market Segmentation: The company is exploring overlaps between different customer segments (oral, IV, and injectable users) but acknowledges that the at-home kit may attract a distinct user base focused on acute therapy.
• Future Marketing Strategies: Plans to leverage social media and influencer marketing to promote new products, particularly targeting the biohacker and anti-aging communities.

Overall, Niagen Bioscience Inc. reported a solid quarter with growth in revenue and net income, while also facing competitive challenges and operational adjustments. The company remains optimistic about its growth trajectory, driven by innovative product launches and increased market awareness.